|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-03
|
$382,013
|
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Molecular Biology in Clinical Oncology Workshop
|
5R25CA057732-26
|
$249,978
|
|
SAWYERS, CHARLES
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Enhanced Training and Mentorship of Hematologic Oncologists
|
2R25CA168526-06
|
$306,150
|
|
SUNG, LILLIAN
|
AMERICAN SOCIETY OF HEMATOLOGY
|
|
Rapid Point of Care Detection of HPV-Associated Malignancies
|
5UG3CA211415-02
|
$338,933
|
|
ANDERSON, KAREN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
IDO-Expressing Immunoregulatory Dendritic Cells
|
5R01CA103320-15
|
$307,800
|
|
MUNN, DAVID
|
AUGUSTA UNIVERSITY
|
|
Development of cell-free DNA assays for HCC screening and liquid biopsy
|
5R01CA202769-03
|
$397,877
|
|
SU, YING-HSIU
|
BARUCH S. BLUMBERG INSTITUTE
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-03
|
$706,386
|
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-13
|
$249,638
|
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
De facto Target of Histone Deacetylase Inhibitors
|
5R21CA215591-02
|
$172,369
|
|
SUN, ZHENG
|
BAYLOR COLLEGE OF MEDICINE
|
|
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
|
5R01CA181183-05
|
$361,050
|
|
NUCERA, CARMELO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Randomized Trial of a Mammography Decision Aid for Women Aged 75 and Older
|
5R01CA181357-05
|
$414,552
|
|
SCHONBERG, MARA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterizing the signaling pathways that regulate Skp2 oncogenic function
|
5R01CA200573-03
|
$395,738
|
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization
|
5R01CA200651-03
|
$383,385
|
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Integrative genomic framework for dissecting regulatory mechanisms underlying hepatocellular carcinoma
|
5R21CA209940-02
|
$175,001
|
|
POCHET, NATHALIE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Redefining Normal: personalized CA125 cutpoints for ovarian cancer screening
|
5R01CA193965-03
|
$371,704
|
|
TERRY, KATHRYN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Genetic Determinants of Barretts Esophagus and Esophageal Adenocarcinoma
|
5U54CA163060-07
|
$1,283,594
|
|
CHAK, AMITABH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Oncology Nurse IMPACT:Improving Communication with Patients about Clinical Trial
|
5R25CA177574-05
|
$130,966
|
|
DALY, BARBARA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cancer-focused Summer Undergraduate Research (CanSUR) Program
|
1R25CA225461-01
|
$323,501
|
|
JACKSON, MARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Small Molecule Activators of PP2A (SMAPs) for Prostate Cancer Therapy
|
5R01CA181654-04
|
$374,305
|
|
NARLA, GOUTHAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Glial tumor image-guided surgery and treatment
|
5R01CA209921-03
|
$519,467
|
|
HOLLER, EGGEHARD
|
CEDARS-SINAI MEDICAL CENTER
|
|
Identification of microbial biomarkers for hepatocellular carcinoma in a multi-ethnic population of patients with nonalcoholic fatty liver disease
|
1R21CA225623-01
|
$176,514
|
|
HUSSAIN, SHEHNAZ
|
CEDARS-SINAI MEDICAL CENTER
|
|
Connecting Genomic Alterations in Liposarcomas with Drug Responses and Identification of New Therapeutic Approaches
|
5R01CA200992-03
|
$363,125
|
|
KOEFFLER, HAROLD
|
CEDARS-SINAI MEDICAL CENTER
|
|
Development of GIFT4: a B cell focused immunotherapy for cancer
|
5R44CA217365-02
|
$999,997
|
|
GUYRE, PAUL
|
CELDARA MEDICAL, LLC
|
|
A Phase I trial combining IV fenretinide and IV safingol to target overproduction
|
5R44CA183316-03
|
$473,425
|
|
SIMPSON, WILLIAM
|
CERRX, INC.
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-10
|
$374,304
|
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cellular Predisposition to Retinoblastoma Tumorigenesis
|
5R01CA137124-06
|
$336,150
|
$84,038
|
COBRINIK, DAVID
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Tissue Specific Regulation of Diabetes-Associated Cancer Growth
|
5R01CA177771-05
|
$328,888
|
|
STENINA, OLGA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Roles and Regulation of wild-type and mutant forms of p53
|
5P01CA087497-17
|
$1,885,586
|
|
PRIVES, CAROL
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
The mechanisms driving brain oncogenesis by FGFR-TACC gene fusions
|
5R01CA178546-05
|
$366,858
|
|
IAVARONE, ANTONIO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer
|
1U01CA225431-01
|
$644,727
|
|
SCHWARTZ, LAWRENCE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-26
|
$301,545
|
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Targeting the cytokine circuitry of KRAS-driven lung cancer
|
5R01CA190394-04
|
$394,578
|
|
BARBIE, DAVID
|
DANA-FARBER CANCER INST
|
|
Stroma-mediated clonal evolution in Multiple Myeloma
|
5R01CA181683-05
|
$353,770
|
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
|
5R01CA205954-03
|
$703,249
|
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies
|
5U54CA193461-04
|
$2,288,376
|
|
MICHOR, FRANZISKA
|
DANA-FARBER CANCER INST
|
|
Humanized bone marrow-like model to study patient-derived myeloma xenografts
|
5R01CA196664-03
|
$537,912
|
|
MITSIADES, CONSTANTINE
|
DANA-FARBER CANCER INST
|
|
Functional analysis of the Tip60 complex
|
5R01CA093602-14
|
$311,400
|
|
PRICE, BRENDAN
|
DANA-FARBER CANCER INST
|
|
Metabolic Vulnerabilities in Melanoma Tumors
|
5R01CA181217-05
|
$347,077
|
|
PUIGSERVER, PERE
|
DANA-FARBER CANCER INST
|
|
The function of cyclin C in tumorigenesis
|
5R01CA190509-04
|
$453,569
|
|
SICINSKI, PETER
|
DANA-FARBER CANCER INST
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
5R01CA216273-02
|
$740,321
|
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
To enhance breast cancer survivorship of Asian Americans
|
5R01CA203719-03
|
$576,193
|
|
IM, EUN-OK
|
DUKE UNIVERSITY
|
|
Experimental Therapy for Brain Tumors
|
1P01CA225622-01
|
$2,170,371
|
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
Developing knowledge models to enable rapid learning in radiation therapy
|
5R01CA201212-03
|
$441,708
|
|
WU, QINGRONG
|
DUKE UNIVERSITY
|
|
Novel Strategies for Cancer Immunotherapy in Stem Cell Transplant
|
5R01CA136934-10
|
$357,750
|
|
YANG, YIPING
|
DUKE UNIVERSITY
|
|
The PDX Integrator- Re-purposing KOMP2 informatics to widely disseminate data from Patient Derived Xenografts
|
5U24CA204781-03
|
$413,604
|
|
PARKINSON, HELEN
|
EUROPEAN MOLECULAR BIOLOGY LABORATORY
|
|
Adult Leukemia Research Center
|
2P01CA018029-42A1
|
$3,990,001
|
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Serrated Colorectal Cancer: An Emerging Disease Subtype
|
5R01CA196337-04
|
$885,578
|
|
NEWCOMB, POLLY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Validation of a disposable biospecimen collection system with integral refrigeration for preserving the phosphoproteome
|
1R21CA225507-01
|
$280,976
|
|
PAULOVICH, AMANDA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
Total relevant funding to Pituitary for this search: $1,138,158
|